These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19946587)

  • 1. Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe sepsis: a case report.
    Barra L; Shum J; Pickering JG; Kao R
    J Med Case Rep; 2009 Nov; 3():109. PubMed ID: 19946587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; Booth FV
    Surgery; 2007 Apr; 141(4):548-61. PubMed ID: 17431957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy.
    Dhainaut JF;
    Curr Med Res Opin; 2008 Apr; 24(4):1187-97. PubMed ID: 18348744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
    Laterre PF; Macias WL; Janes J; Williams MD; Nelson DR; Girbes AR; Dhainaut JF; Abraham E
    Crit Care; 2008; 12(5):R117. PubMed ID: 18786266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock.
    Spapen H; Nguyen DN; Troubleyn J; Huyghens L; Schiettecatte J
    Crit Care; 2010; 14(2):R54. PubMed ID: 20374626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
    Barie PS; Hydo LJ; Shou J; Eachempati SR
    Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drotrecogin alfa activated in clinical practice and the current evidences.
    Soares M; Machado FO; Torres VB; Salluh JI; Amaral AC
    Rev Bras Ter Intensiva; 2008 Jun; 20(2):173-7. PubMed ID: 25307006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.
    Vincent JL; Nadel S; Kutsogiannis DJ; Gibney RT; Yan SB; Wyss VL; Bailey JE; Mitchell CL; Sarwat S; Shinall SM; Janes JM
    Crit Care; 2005 Aug; 9(4):R331-43. PubMed ID: 16137345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of thrombosis, fibrinolysis, and inflammation in patients with severe sepsis due to community-acquired pneumonia with and without Streptococcus pneumoniae.
    Vail GM; Xie YJ; Haney DJ; Barnes CJ
    Infection; 2009 Aug; 37(4):358-64. PubMed ID: 19169631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.
    Nadel S; Goldstein B; Williams MD; Dalton H; Peters M; Macias WL; Abd-Allah SA; Levy H; Angle R; Wang D; Sundin DP; Giroir B;
    Lancet; 2007 Mar; 369(9564):836-843. PubMed ID: 17350452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study.
    Vincent JL; Laterre PF; Decruyenaere J; Spapen H; Raemaekers J; Damas F; Rogiers P; Sartral M; Haentjens T; Nelson D; Janes J
    Acta Clin Belg; 2008; 63(1):25-30. PubMed ID: 18386762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drotrecogin alfa (activated): real-life use and outcomes for the UK.
    Rowan KM; Welch CA; North E; Harrison DA
    Crit Care; 2008; 12(2):R58. PubMed ID: 18430215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).
    Levi M; Levy M; Williams MD; Douglas I; Artigas A; Antonelli M; Wyncoll D; Janes J; Booth FV; Wang D; Sundin DP; Macias WL;
    Am J Respir Crit Care Med; 2007 Sep; 176(5):483-90. PubMed ID: 17556722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis.
    Vincent JL; O'Brien J; Wheeler A; Wittebole X; Garg R; Trzaskoma BL; Sundin DP
    Crit Care; 2006; 10(3):R74. PubMed ID: 16684364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
    Abraham E; Laterre PF; Garg R; Levy H; Talwar D; Trzaskoma BL; François B; Guy JS; Brückmann M; Rea-Neto A; Rossaint R; Perrotin D; Sablotzki A; Arkins N; Utterback BG; Macias WL;
    N Engl J Med; 2005 Sep; 353(13):1332-41. PubMed ID: 16192478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.
    Martin G; Brunkhorst FM; Janes JM; Reinhart K; Sundin DP; Garnett K; Beale R
    Crit Care; 2009; 13(3):R103. PubMed ID: 19566927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).
    Shorr AF; Nelson DR; Wyncoll DL; Reinhart K; Brunkhorst F; Vail GM; Janes J
    Crit Care; 2008; 12(2):R45. PubMed ID: 18394162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy.
    Camporota L; Corno E; Menaldo E; Smith J; Lei K; Beale R; Wyncoll D
    Crit Care; 2008; 12(6):R163. PubMed ID: 19094233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.
    Bertolini G; Rossi C; Anghileri A; Livigni S; Addis A; Poole D
    Intensive Care Med; 2007 Mar; 33(3):426-34. PubMed ID: 17325836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.